BRPI1013377A2 - formulação de quinonas de tocotrienol para o tratamento de doenças oftálmicas - Google Patents

formulação de quinonas de tocotrienol para o tratamento de doenças oftálmicas

Info

Publication number: BRPI1013377A2
Authority: BR; Brazil
Prior art keywords: formulation; treatment; ophthalmic diseases; tocotrienol quinone; tocotrienol
Prior art date: 2009-04-28

Application number

BRPI1013377A

Other languages

English (en)

Inventor

M Miller Guy

Kheifets Viktoria

D Shrader William

Original Assignee

Edison Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-04-28

Filing date

2010-04-27

Publication date

2017-03-21

2010-04-27 Application filed by Edison Pharmaceuticals Inc filed Critical Edison Pharmaceuticals Inc

2017-03-21 Publication of BRPI1013377A2 publication Critical patent/BRPI1013377A2/pt

Links

AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 title 2
GJJVAFUKOBZPCB-UHFFFAOYSA-N 2-methyl-2-(4,8,12-trimethyltrideca-3,7,11-trienyl)-3,4-dihydrochromen-6-ol Chemical compound OC1=CC=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-UHFFFAOYSA-N 0.000 title 1
201000010099 disease Diseases 0.000 title 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
238000009472 formulation Methods 0.000 title 1
239000000203 mixture Substances 0.000 title 1
229930003802 tocotrienol Natural products 0.000 title 1
239000011731 tocotrienol Substances 0.000 title 1
235000019148 tocotrienols Nutrition 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Landscapes

Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Epidemiology (AREA)
Ophthalmology & Optometry (AREA)
Diabetes (AREA)
Cardiology (AREA)
Psychiatry (AREA)
Physiology (AREA)
Psychology (AREA)
Heart & Thoracic Surgery (AREA)
Nutrition Science (AREA)
Hematology (AREA)
Pain & Pain Management (AREA)
Obesity (AREA)
Hospice & Palliative Care (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

BRPI1013377A 2009-04-28 2010-04-27 formulação de quinonas de tocotrienol para o tratamento de doenças oftálmicas BRPI1013377A2 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US21479509P	2009-04-28	2009-04-28
US31873710P	2010-03-29	2010-03-29
PCT/US2010/032621 WO2010126909A1 (en)	2009-04-28	2010-04-27	Formulation of tocotrienol quinones for the treatment of ophthalmic diseases

Publications (1)

Publication Number	Publication Date
BRPI1013377A2 true BRPI1013377A2 (pt)	2017-03-21

Family

ID=42236620

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI1013377A BRPI1013377A2 (pt)	2009-04-28	2010-04-27	formulação de quinonas de tocotrienol para o tratamento de doenças oftálmicas

Country Status (8)

Country	Link
US (3)	US20100273892A1 (pt)
EP (1)	EP2424494A1 (pt)
JP (4)	JP2012525397A (pt)
BR (1)	BRPI1013377A2 (pt)
CA (1)	CA2759984A1 (pt)
EA (1)	EA201101576A1 (pt)
MX (1)	MX2011011310A (pt)
WO (1)	WO2010126909A1 (pt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2580584C (en)	2003-09-19	2015-07-28	Galileo Pharmaceuticals, Inc.	Use of alpha-tocotrienol for treatment of mitochondrial diseases
CA2610152C (en)	2005-06-01	2018-04-10	Edison Pharmaceuticals, Inc.	Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
EA019675B1 (ru)	2006-02-22	2014-05-30	Эдисон Фармасьютикалз, Инк.	Редокс-активные терапевтические средства для лечения митохондриальных заболеваний и модуляции биомаркера коэнзима q
EP3018122B1 (en)	2007-11-06	2018-10-10	BioElectron Technology Corporation	4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases
CA2708961C (en)	2008-01-08	2017-03-28	Ptc Therapeutics, Inc.	(het)aryl-p-quinone derivatives for treatment of mitochondrial diseases
WO2009111576A2 (en)	2008-03-05	2009-09-11	Edison Pharmaceuticals, Inc.	2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES
WO2009158348A1 (en) *	2008-06-25	2009-12-30	Edison Pharmaceuticals, Inc.	2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases
BRPI0918139B1 (pt)	2008-09-10	2024-04-30	Ptc Therapeutics, Inc	Composição, alimento medicinal ou funcional, suplemento alimentar ou dietético para tratamento de distúrbios de desenvolvimento pervasivos com terapêuticos redox-ativos
CA2740773A1 (en)	2008-10-14	2010-04-22	Edison Pharmaceuticals, Inc.	Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells
CN102264730B (zh)	2008-10-28	2016-04-13	爱迪生药物公司	用于生产生育三烯酚及衍生物的方法
JP2012525399A (ja)	2009-04-28	2012-10-22	エジソンファーマシューティカルズ，インコーポレイテッド	トコトリエノールキノンを用いる、レーバー遺伝性視神経症および優性遺伝性視神経萎縮症の治療
CN102548548B (zh) *	2009-06-10	2017-09-01	米拓科技有限公司（卢森堡）	用于医学和兽医学的眼科药物组合物
SI2470168T1 (en) *	2009-08-26	2018-05-31	Bioelectron Technology Corporation	Procedures for the prevention and treatment of brain ischemia
EP2519232A1 (en) *	2009-12-31	2012-11-07	Edison Pharmaceuticals, Inc.	Treatment of leigh syndrome and leigh-like syndrome with tocotrienol quinones
JP2013523816A (ja) *	2010-04-06	2013-06-17	エジソンファーマシューティカルズ，インコーポレイテッド	毛細血管拡張性運動失調症の治療
WO2012068552A1 (en) *	2010-11-19	2012-05-24	Edison Pharmaceuticals, Inc.	Methods for improving blood glucose control
WO2012167236A1 (en)	2011-06-03	2012-12-06	Mitotech Sa	Oral formulations of mitochondrially-targeted antioxidants and their preparation and use
WO2012174286A1 (en)	2011-06-14	2012-12-20	Edison Pharmaceuticals, Inc.	Catechol derivatives for treatment of oxidative stress diseases
WO2013006737A1 (en) *	2011-07-06	2013-01-10	Edison Pharmaceuticals, Inc.	Treatment of methylmalonic aciduria, isovaleric aciduria, and other organic acidurias with tocotrienol quinones
WO2013006736A1 (en) *	2011-07-06	2013-01-10	Edison Pharmaceuticals, Inc	Treatment of leigh syndrome and leigh-like syndrome, including complications of sucla2 mutations, with tocotrienol quinones
JP2014520894A (ja)	2011-07-19	2014-08-25	エジソンファーマシューティカルズ，インコーポレイテッド	非アルファトコトリエノールの存在下でのアルファトコトリエノールの選択的酸化のための方法
EP2573063A1 (en)	2011-09-23	2013-03-27	DSM IP Assets B.V.	Process for preparing chiral quinone
CA2883879A1 (en)	2012-09-07	2014-03-13	Edison Pharmaceuticals, Inc.	Quinone derivatives for use in the modulation of redox status of individuals
CA2906145A1 (en)	2013-03-15	2014-09-18	Ptc Therapeutics, Inc.	Alkyl-heteroaryl substituted quinone derivatives for treatment of oxidative stress disorders
US9296712B2 (en)	2013-03-15	2016-03-29	Edison Pharmaceuticals, Inc.	Resorufin derivatives for treatment of oxidative stress disorders
US9670170B2 (en)	2013-03-15	2017-06-06	Bioelectron Technology Corporation	Resorufin derivatives for treatment of oxidative stress disorders
US9868711B2 (en)	2013-03-15	2018-01-16	Bioelectron Technology Corporation	Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders
WO2015183963A2 (en) *	2014-05-28	2015-12-03	Stealth Peptides International, Inc.	Therapeutic compositions including redox-active parabenzoquinones and uses thereof
WO2016100579A1 (en)	2014-12-16	2016-06-23	Edison Pharmaceuticals, Inc.,	Polymorphic and amorphous forms of (r)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide
WO2017106786A1 (en)	2015-12-16	2017-06-22	Bioelectron Technology Corporation	Improved methods for enriching alpha-tocotrienol from mixed tocol compositions
CN113024369A (zh)	2015-12-17	2021-06-25	Ptc医疗公司	用于治疗氧化应急障碍的化合物
JP2018083799A (ja)	2016-11-15	2018-05-31	バイオエレクトロンテクノロジーコーポレイション	２−置換アミノ−ナフト［１，２−ｄ］イミダゾール−５−オン化合物またはその製薬学上許容される塩
US20190365705A1 (en) *	2017-01-20	2019-12-05	Ohio State Innovation Foundation	Topical tocotrienol compositions and methods of increasing skin stem cells
JP7586815B2 (ja)	2018-10-17	2024-11-19	ピーティーシーセラピューティクス，インコーポレイテッド	α－シヌクレイノパチー、タウオパチー、および他の障害を抑制および処置するための２，３，５－トリメチル－６－ノニルシクロヘキサ－２，５－ジエン－１，４－ジオン
CN118175991A (zh)	2021-07-08	2024-06-11	Ptc医疗公司	包含2,3,5-三甲基-6-壬基环己-2,5-二烯-1,4-二酮的药物组合物
EP4727532A1 (en) *	2023-06-16	2026-04-22	PTC Therapeutics, Inc.	Methods for increasing vatiquinone plasma exposure with food
CN121909176A (zh) *	2023-07-21	2026-04-21	康德生物医疗有限公司	与治疗和预防利氏综合征有关的方法、组合物和用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5318993A (en) *	1993-04-16	1994-06-07	Bristol-Myers Squibb Company	Antihyperlipidemic benzoquinones
EP1378753B1 (en) *	2002-07-01	2006-05-31	Santhera Pharmaceuticals (Schweiz) GmbH	A screening method and compounds for treating Friedreich Ataxia
US7015243B2 (en) *	2003-08-28	2006-03-21	Allergan, Inc.	Cyclohexyl prostaglandin analogs as EP4-receptor agonists
CA2580584C (en) *	2003-09-19	2015-07-28	Galileo Pharmaceuticals, Inc.	Use of alpha-tocotrienol for treatment of mitochondrial diseases
WO2005032478A2 (en) *	2003-10-01	2005-04-14	Yasoo Health, Inc.	Treatment for diabetic microvascular and macrovascular complications
US8182990B2 (en) *	2004-03-18	2012-05-22	Rusk Intellectual Reserve Ag	Method for diagnosing or predicting susceptibility to optic neuropathy
CA2610152C (en) *	2005-06-01	2018-04-10	Edison Pharmaceuticals, Inc.	Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
EA019675B1 (ru) *	2006-02-22	2014-05-30	Эдисон Фармасьютикалз, Инк.	Редокс-активные терапевтические средства для лечения митохондриальных заболеваний и модуляции биомаркера коэнзима q
WO2008157747A1 (en) *	2007-06-21	2008-12-24	The Jackson Laboratory	Use of inhibition of exonuclease 1 in methods for therapy and diagnostic of neurodegenerative diseases, eye diseases, and mitochondrial disorders

2010
- 2010-04-27 MX MX2011011310A patent/MX2011011310A/es not_active Application Discontinuation
- 2010-04-27 EA EA201101576A patent/EA201101576A1/ru unknown
- 2010-04-27 BR BRPI1013377A patent/BRPI1013377A2/pt not_active Application Discontinuation
- 2010-04-27 US US12/768,554 patent/US20100273892A1/en not_active Abandoned
- 2010-04-27 JP JP2012508606A patent/JP2012525397A/ja not_active Withdrawn
- 2010-04-27 WO PCT/US2010/032621 patent/WO2010126909A1/en not_active Ceased
- 2010-04-27 EP EP10715649A patent/EP2424494A1/en not_active Withdrawn
- 2010-04-27 CA CA2759984A patent/CA2759984A1/en not_active Abandoned
2013
- 2013-01-10 US US13/738,827 patent/US20140031433A1/en not_active Abandoned
2014
- 2014-11-20 JP JP2014235405A patent/JP2015038154A/ja not_active Withdrawn
2016
- 2016-04-11 JP JP2016078793A patent/JP2016128523A/ja active Pending
2017
- 2017-08-07 JP JP2017152470A patent/JP2017193594A/ja active Pending
- 2017-12-20 US US15/849,557 patent/US20180116978A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20180116978A1 (en)	2018-05-03
JP2015038154A (ja)	2015-02-26
WO2010126909A1 (en)	2010-11-04
US20100273892A1 (en)	2010-10-28
US20140031433A1 (en)	2014-01-30
CA2759984A1 (en)	2010-11-04
EA201101576A1 (ru)	2012-04-30
MX2011011310A (es)	2011-11-18
JP2012525397A (ja)	2012-10-22
JP2016128523A (ja)	2016-07-14
JP2017193594A (ja)	2017-10-26
EP2424494A1 (en)	2012-03-07

Legal Events

Date	Code	Title	Description
2017-08-15	B25D	Requested change of name of applicant approved	Owner name: BIOELECTRON TECHNOLOGY CORPORATION (US)
2018-01-16	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-04-10	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2019-01-02	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]	Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI
2019-01-29	B06T	Formal requirements before examination [chapter 6.20 patent gazette]
2019-04-16	B11E	Dismissal acc. art. 34 of ipl - requirements for examination incomplete
2020-09-24	B11T	Dismissal of application maintained [chapter 11.20 patent gazette]

Publication	Publication Date	Title
LTC2785706I2 (lt)	2023-07-10	Pakeistieji 4-fenil-piridinai, skirti su nk-receptoriumi susijusių ligų gydymui
ZA201208535B (en)	2016-06-29	Formulations of quinones for the treatment of ophthalmic diseases
CO7061081A2 (es)	2014-09-19	Derivados macrocíclicos para el tratamiento de enfermedades
PT2504005E (pt)	2014-01-10	Utilização de derivados de 1,3-difenilprop-2-en-1-ona para tratamento de doenças hepáticas
PT2925757T (pt)	2018-01-09	Compostos e composições para o tratamento de doenças parasitárias
IL229017B (en)	2020-09-30	Oxidative retinal diseases
BR112014013843A2 (pt)	2017-07-04	uso de dispositivos para o tratamento de doenças neurológicas
EP2621499A4 (en)	2014-04-09	METHODS OF TREATING ALLERGIC DISEASES
IL236221A (en)	2017-12-31	History of theophyridone and pharmacological preparations containing them for the treatment of diseases
PT2632300T (pt)	2018-05-02	Almofada cervical para o tratamento de doenças da coluna cervical
EP2424360A4 (en)	2012-10-03	TOPICAL, PERIOCULAR OR INTRAOCULAR USE OF TOCOTRIENOLS FOR THE TREATMENT OF OPHTHALMIC DISEASES
IL208357A0 (en)	2010-12-30	Spiro-indole derivatives for the treatment of parasitic diseases
PT2872497T (pt)	2017-04-24	Derivados de cromanilo para o tratamento de doenças mitocondriais
BR112012004836A2 (pt)	2019-09-24	pirazinilpiridinas úteis para o tratamento de doenças proliferativas
BRPI0917440A2 (pt)	2015-12-01	composições farmacêuticas oftálmicas para o tratamento de patologias neoangiogênicas do olho
BR112013030370A2 (pt)	2017-08-08	compostos de quinona para tratamento de doenças mediadas por ape1
GB0906159D0 (en)	2009-05-20	Drug combination for the treatment of proteostatic diseases
IL230960A0 (en)	2014-03-31	A device for the treatment of eye disease
PT2525796T (pt)	2016-07-11	Solução aquosa incluindo 3-quinuclidinonas para o tratamento de doenças hiperproliferativas, auto-imunes e cardíacas
PT2632475T (pt)	2016-12-09	Composições para o tratamento de úlceras periféricas de várias origens
IL230959B (en)	2018-05-31	A device for the treatment of eye disease
PL2605769T3 (pl)	2017-01-31	Pochodne benzochinonu do leczenia chorób mitochondrialnych oczu
PL392436A1 (pl)	2012-03-26	Pochodne arylosulfonamidów do leczenia chorób odśrodkowego układu nerwowego
ITRM20120530A1 (it)	2014-05-01	Compounds for use in the treatment of parasitic diseases
SG11201508061UA (en)	2015-10-29	Artificial transcription factors for the treatment of diseases caused by opa1 haploinsufficiency